scispace - formally typeset
B

Barbara Ryan

Researcher at Trinity College, Dublin

Publications -  174
Citations -  3224

Barbara Ryan is an academic researcher from Trinity College, Dublin. The author has contributed to research in topics: Preparedness & Infliximab. The author has an hindex of 29, co-authored 161 publications receiving 2729 citations. Previous affiliations of Barbara Ryan include Manchester Royal Infirmary & University of Southern Queensland.

Papers
More filters
Journal ArticleDOI

Changes in Presentation of Celiac Disease in Ireland From the 1960s to 2015.

TL;DR: The clinical presentation of celiac disease changed significantly in Ireland from 1960 through 2015, and the age of presentation in adulthood increased over this time period, as did the proportions of patients with nonclassical or subclinical disease.
Journal ArticleDOI

Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis.

TL;DR: The development of retinal vein thrombosis in a patient with ulcerative colitis, occurring 2 weeks after his sixth infliximab infusion, is described in a 67-year-old man who presented with 6-week history of bloody diarrhoea per day and weight loss.
Journal ArticleDOI

Safety of infliximab in 10 years of clinical practice

TL;DR: Infliximab therapy seems to be safe and efficacious in the long term, although the development of malignancy remains a concern, and there has not seen an increased risk of serious infection within this cohort of patients.
Journal ArticleDOI

Emergency management communication: The paradox of the positive in public communication for preparedness

TL;DR: In this paper, a study of government communication relating to emergency management preparedness examines an Australian context to understand the types of messages preparing community members for natural hazards, finding that agencies employ a two-track approach combining warranting and engagement messages.
Journal ArticleDOI

Effectiveness of the community-based Low Vision Service Wales: a long-term outcome study

TL;DR: Evidence is provided that the effect of the LVSW persists over a period of 18 months; disability is reduced from baseline, and use of low-vision aids (LVAs) remains high.